Skip to main content

Advertisement

Table 2 Metabolic parameters

From: L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function

Variable Control DM+NS Pre-treatment DM+LC(L) DM+LC(H)
Body Weight (g) 44.4 ± 3.4 40.1 ± 2.1 32.0 ± 2.8××## 40.3 ± 2.0 41.8 ± 5.6
Liver weight (g) 1.3 ± 0.3 2.4 ± 0.5** 2.0 ± 0.4* 1.9 ± 0.3*# 1.8 ± 0.2#
Relative liver weight 0.04 ± 0.01 0.06 ± 0.01** 0.06 ± 0.01 0.05 ± 0.00# 0.05 ± 0.00##
FFA in liver (L/g·cm) 1.7 ± 0.1 2.0 ± 0.3* 1.8 ± 0.2 1.9 ± 0.3 1.8 ± 0.1
TG in liver (mmol/L) 0.23 ± 0.04 1.16 ± 0.6** 0.34 ± 0.2## 0.55 ± 0.09# 0.48 ± 0.1##
TG in plasma (mmol/L) 1.2 ± 0.1 3.9 ± 2.3** 1.7 ± 0.6 2.2 ± 1.0 1.6 ± 0.4
LC in liver (μmol/L) 16.9 ± 3.4 11.2 ± 2.6* 12.1 ± 3.1 14.9 ± 1.9 12.6 ± 4.1
ALC in liver (μmol/L) 1.0 ± 0.2 0.8 ± 0.3 1.0 ± 0.7 1.4 ± 0.2 2.3 ± 0.9**##
LC/ALC 16.9 ± 4.7 16.6 ± 5.9 15.4 ± 6.6 11.3 ± 2.8 5.6 ± 1.5**##
  1. Control: control group, DM+NS: diabetic group, pre-treatment: preventive group, DM+LC (L): low-dose therapeutic group, DM+LC (H): high-dose therapeutic group. All values are expressed as the mean ± S.E. using the repeated measures method. *P < 0.05, **P < 0.01 (compared to control group), #P < 0.05, ##P < 0.01 (compared to diabetic group).